A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).

被引：19

作者：

Choueiri, Toni K.

Apolo, Andrea B.

Powles, Thomas

Escudier, Bernard

Aren, Osvaldo Rudy

Shah, Amishi

Kessler, Elizabeth Riley

Hsieh, James J.

Zhang, Joshua

Simsek, Burcin

Scheffold, Christian

Motzer, Robert J.

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Natl Canc Inst, Natl Inst Hlth, Genitourinary Malignancies Branch, Ctr Canc Res, Bethesda, MD USA

[3] Queen Mary Univ London, Barts Canc Inst, London, England

[4] Saclay Univ, INSERM, U1015, Villejuif, France

[5] Inst Nacl Canc, Santiago, Chile

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[7] UniColorado Anschutz Med Ctr, Aurora, CO USA

[8] Washington Univ Med Sch, St Louis, MO USA

[9] Bristol Myers Squibb, Princeton, NJ USA

[10] Exelixis Inc, San Francisco, CA USA

[11] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS4598

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

TPS4598

引用

页数：1